Abstract: Thiazolide compounds, such as nitazoxanide and/or tizoxanide, may be used against viruses belonging to the Picornaviridae family or the Paramyxoviridae family.

Abstract: Provided are methods of treating a disease or condition associated with an increased level of expression of a protein disulfide-isomerase A3 (PDIA3) by administering to a subject with an increased level of expression of PDIA3 a PDIA3-inhibiting effective amount of a thiazolide compound, such as nitazoxanide or tizoxanide. Also provided are methods of screening for therapeutic agents based on PDIA3 inhibition.

Abstract: Thiazolide compounds, such as nitazoxanide and/or tizoxanide, may be used against viruses belonging to the Picornaviridae family or the Paramyxoviridae family.

Abstract: A computer-implemented method and system for supporting a person at a site, venue, or location where the person may have a requirement. The method and system include storing a requirement code in a handheld device, and storing the requirement code and at least one characteristic relating to the requirement code in a requirement certification database. The requirement code is transmitted from the handheld device to a sensor at the site, and action data is received by a facility of the site from the requirement certification database. The action data is indicative of an action to be performed by the facility, dependent on the requirement code and the at least one characteristic, such that the facility adapts its function to a requirement of the person having the requirement.

Abstract: Provided are methods of treating a disease or condition associated with an increased level of expression of a protein disulfide-isomerase A3 (PDIA3) by administering to a subject with an increased level of expression of PDIA3 a PDI A3-inhibiting effective amount of a thiazolide compound, such as nitazoxanide or tizoxanide. Also provided are methods of screening for therapeutic agents based on PDIA3 inhibition.

Abstract: A computer-implemented method and system for supporting a person at a site, venue, or location where the person may have a requirement. The method and system include storing a requirement code in a handheld device, and storing the requirement code and at least one characteristic relating to the requirement code in a requirement certification database. The requirement code is transmitted from the handheld device to a sensor at the site, and action data is received by a facility of the site from the requirement certification database. The action data is indicative of an action to be performed by the facility, dependent on the requirement code and the at least one characteristic, such that the facility adapts its function to a requirement of the person having the requirement.

Abstract: A computer-implemented method and system for supporting a person at a site, venue, or location where the person may have a requirement. The method and system include storing a requirement code in a handheld device, and storing the requirement code and at least one characteristic relating to the requirement code in a requirement certification database. The requirement code is transmitted from the handheld device to a sensor at the site, and action data is received by a facility of the site from the requirement certification database. The action data is indicative of an action to be performed by the facility, dependent on the requirement code and the at least one characteristic, such that the facility adapts its function to a requirement of the person having the requirement.

Abstract: A computer-implemented method and system for supporting a person at a site, venue, or location where the person may have a requirement. The method and system include storing a requirement code in a handheld device, and storing the requirement code and at least one characteristic relating to the requirement code in a requirement certification database. The requirement code is transmitted from the handheld device to a sensor at the site, and action data is received by a facility of the site from the requirement certification database. The action data is indicative of an action to be performed by the facility, dependent on the requirement code and the at least one characteristic, such that the facility adapts its function to a requirement of the person having the requirement.

Abstract: Thiazolide compounds, such as nitazoxanide and/or tizoxanide, may be used against viruses belonging to the Picornaviridae family or the Paramyxoviridae family.

Abstract: A method and system for synchronizing source code files and related documentation during software development of a software product including a plurality of files, each file being assigned to a owner, including the steps of: an Event Manager module detecting a change made by a programmer in a file of the plurality of files and saving the status of the file before the change; an Event Handler module identifying the owner of the file containing the detected change; the Event Handler module notifying the owner of the detected change; prompting the owner in approving or rejecting the change; responsive to the owner input, synchronizing the plurality of files or deleting the detected change rolling back to the saved status.

Abstract: A method and system for synchronizing source code files and related documentation during software development of a software product including a plurality of files, each file being assigned to a owner, including the steps of: an Event Manager module detecting a change made by a programmer in a file of the plurality of files and saving the status of the file before the change; an Event Handler module identifying the owner of the file containing the detected change; the Event Handler module notifying the owner of the detected change; prompting the owner in approving or rejecting the change; responsive to the owner input, synchronizing the plurality of files or deleting the detected change rolling back to the saved status.

Abstract: A compound comprising a cyclopentanone, cyclopentenone, cyclohexanone or cyclohexenone group, wherein a first ring carbon atom carries an —SR substituent, R is a substituted or unsubstituted alkyl, alkenyl, alkynyl, aryl, aralkyl, aralkenyl, or aralkynyl group that, optionally, includes at least one heteroatom in its carbon skeleton, the remaining available ring carbon atoms are optionally substituted, and said compound either: —(a) is more soluble in water at a temperature of 20-40° C.; (b) is less lipophilic; and/or, (c) has a greater therapeutic index; or; (d) is less soluble in water at a temperature of 20-40° C.; (e) is more lipophilic; and/or, (f) has a greater therapeutic index; than an equivalent cyclohex-2-en-1-one or cyclopent-2-en-1-one derivative in which a hydrogen atom replaces said —SR group.

Abstract: A method and system for identifying, locating and providing navigational instructions among distributed items is disclosed. The method includes the steps of designating a plurality of items, identifying each of the items, accessing a data base to obtain at least location information associated with each identified item, providing a map of the location of each item, determining a distance to each item, determining a first item based on a user's position and sorting the list by distance with respect to the first item and providing navigational instructions to each item on the list.

Abstract: A compound of formula (I) or (II): wherein A is hydrogen or CR1R2; Y and Z are each, independently, hydrogen or a halogen; X is —NR4R5, or R7; R1 is hydrogen, or a substituted or unsubstituted alkyl or alkenyl group containing 1–4 carbon atoms; when X is —NR4R5, R2 is a substituted or unsubstituted alkyl, alkenyl, alkynyl, aryl, aralkyl aralkenyl, or aralkynyl group, that optionally includes at least one heteroatom in its carbon skeleton and contains 1–12 carbon atoms; when X is R7, R2 is an unsubstituted alkyl, alkenyl or alkynyl group, or a substituted or unsubstituted aryl, aralkyl aralkenyl, or aralkynyl group, that optionally includes at least one heteroatom in its carbon skeleton and contains 1–12 carbon atoms; R3 is a substituted or unsubstituted alkyl, alkenyl, alkynyl, aryl, aralkyl aralkenyl, or aralkynyl group, that optionally includes at least one heteroatom in its carbon skeleton and contains 1–12 carbon atoms; R4 is hydrogen, a substituted or unsubstituted alkyl, alkenyl, alkynyl, aryl, aralkyl

Abstract: A compound comprising a cyclopentanone, cyclopentenone, cyclohexanone or cyclohexenone group, wherein a first ring carbon atom carries an —SR substituent, R is a substituted or unsubstituted alkyl, alkenyl, alkynyl, aryl, aralkyl, aralkenyl, or aralkynyl group that, optionally, includes at least one heteroatom in its carbon skeleton, the remaining available ring carbon atoms are optionally substituted, and said compound either:—(a) is more soluble in water at a temperature of 20-40° C.; (b) is less lipophilic; and/or, (c) has a greater therapeutic index; or; (d) is less soluble in water at a temperature of 20-40° C.; (e) is more lipophilic; and/or, (f) has a greater therapeutic index; than an equivalent cyclohex-2-en-1-one or cyclopent-2-en-1-one derivative in which a hydrogen atom replaces said —SR group.

Abstract: A compound of formula (I) or (II): wherein A is hydrogen or CR1R2; Y and Z are each, independently, hydrogen or a halogen; X is —NR4R5, or R7; R1 is hydrogen, or a substituted or unsubstituted alkyl or alkenyl group containing 1-4 carbon atoms; when X is —NR4R5, R2 is a substituted or unsubstituted alkyl, alkenyl, alkynyl, aryl, aralkyl aralkenyl, or aralkynyl group, that optionally includes at least one heteroatom in its carbon skeleton and contains 1-12 carbon atoms; when X is R7, R2 is an unsubstituted alkyl, alkenyl or alkynyl group, or a substituted or unsubstituted aryl, aralkyl aralkenyl, or aralkynyl group, that optionally includes at least one heteroatom in its carbon skeleton and contains 1-12 carbon atoms; R3 is a substituted or unsubstituted alkyl, alkenyl, alkynyl, aryl, aralkyl aralkenyl, or aralkynyl group, that optionally includes at least one heteroatom in its carbon skeleton and contains 1-12 carbon atoms; R4 is hydrogen, a substituted or unsubstituted alkyl, alkenyl, alkynyl, aryl, aralkyl

Abstract: 2-Cyclopenten-1-one and its derivatives comprising the cyclopentenone nucleus as inhibitors of the NF-kB factor, with anti-inflammatory, anti-proliferative-immuno-suppressive, cytoprotective and antiviral activity, the substituents being selected among the ones which do not affect NF-kB inhibitory activity.

Abstract: The present invention provides methods and compositions for inhibiting IKK, as well as methods and compositions for identifying compounds with activity as inhibitors of IKK, and methods and compositions for the treatment of diseases and/or conditions wherein IKK is implicated and inhibition of its activity is desired. In addition, the present invention provides methods and compositions for the improving the therapeutic activity of COX2 inhibitors, comprising administering the COX2 to a subject in combination with a compound that inhibits IKK activity. The present invention further provides compositions that comprise compounds that inhibit IKK and COX2.

Abstract: A compound having a cyclopent-2-ene-1-one ring and also having a double bond directly attached to the ring (in addition to the C═O bond of the cyclopent-1-ene-1-one ring) may be useful in treating various disorders, including viral disorders, cancers, inflammatory disorders, etc.

Abstract: 2-Cyclopenten-1-one and its derivatives comprising the cyclopentenone nucleus as inhibitors of the NF-kB factor, with anti-inflammatory, anti-proliferative, immunosuppressive, cytoprotective and antiviral activity, the substituents being selected among the ones which do not affect the NF-kB inhibitory activity.